<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20251130068162N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-12-19</date_registration>
      <primary_sponsor>Khoram-Abad University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effectiveness of combined injection of platelet-enriched plasma with Botulinum toxic in pain relief and anal fissure repair : a randomized, controlled, clinical trial study</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effectiveness of combined injection of platelet-enriched plasma with Botulinum toxic in pain relief and anal fissure repair : a randomized, controlled, clinical trial study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>144</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/87899</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: ‪Samples are entered into the study based on inclusion and exclusion criteria as available until the sample size is completed. Then, they are assigned to study groups using the block randomization method. For each block, permutations of 3 and 6 are considered so that the prediction of the next assignment is not possible. Randomization will be done using the blockrand package of R software.
To implement the random sequence on the participants in the study, sealed, opaque envelopes with a random sequence are used. A number of envelopes are prepared, and each of the random sequences created is recorded on a card, and the cards are placed inside the envelopes in order. In order to maintain the random sequence, numbering is performed on the outer surface of the envelopes in the same order. Finally, the envelope flaps are glued and placed in boxes in order. At the start of participant enrollment, according to the order of entry of eligible participants into the study, one of the envelopes is opened in order, and the assigned group of that participant is revealed.‬.</study_design>
      <phase>3</phase>
      <hc_freetext>anal fissure.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:‪In this group, each patient receives 0.4 ml of Botox divided into two injections of equal volume on both the right and left lateral sides of the fissure. The injection is performed with a 27-gauge needle. The solution is injected close to the fissure on the lateral side. No sedation or local anesthesia will be used. Patients in the treatment group receive 20 units of botulinum toxin A (Botox 50 units per milliliter), then local anesthesia with all aseptic measures will be performed for PRP injection (ready-made PRP kits are used in this study). Anorectal dilatation is performed in the jack-knife position. Once the anal spasm is relieved, a speculum is placed in the anal canal and the fissure is observed on the clock indicator. The PRP sample is drawn and injected into the fissure bed to the submucosal layer with an insulin needle at a 45-degree angle. We wait for complete hemostasis to be achieved. Dressing is done with all aseptic precautions.‬. Intervention 2: Control group1: In this group, each patient receives 0.4 ml of Botox divided into two equal injections into the right and left lateral sides of the fissure. The injection is performed with a 27-gauge needle. The solution is injected close to the fissure on the lateral side. Sedation or local anesthesia will not be used. Patients in the treatment group receive 20 units of botulinum toxin A (50 units of Botox per ml). Intervention 3: Control group2: In this group, patients apply a fingertip amount of diltiazem gel around their anus every 12 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
"All data can potentially be shared after the individuals are de‑identified

When:
after impression

To whom:
"Researchers

Conditions:
Research use

Where to obtain:
mohadesreza8@gmail.com

How to obtain:
one to six month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>mohamadkazem shahmoradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>kamalvand</address>
        <city>khoramabbad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6816887864</zip>
        <telephone>+98 66 3323 6401</telephone>
        <email>mohadesreza8@gmail.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>mohamadreza mohades</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>kamalvand</address>
        <city>khoramabbad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6816887864</zip>
        <telephone>+98 66 3323 6401</telephone>
        <email>mohadesreza8@gmail.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Individuals must be 18 years of age or older.
must have a history of painful anal fissure (AF) for three months (90 days) or longer prior to screening
No history of diabetes
Presence of a radial fissure with indurated edges observed on anorectal examination
Presence of either anterior or posterior anal fissure
Presence of a skin tag observed during anorectal examination
For individuals who have been using other topical medications, a washout period of at least two weeks prior to the start of the study will be required.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Individuals who are unwilling to undergo AF examination involving the anal canal or perianal region.
Individuals who have undergone lateral sphincterotomy, anal dilation, or any previous interventions
the anal canal or perianal region.Individuals who have used glyceryl trinitrate (GTN) ointment for more than one week during the 4 weeks prior to the screening visit, within a 6-month period.
Anal fissure associated with other conditions (e.g., trauma, HIV infection, fistula, inflammatory bowel disease, perianal sepsis, or malignancy).
Individuals who are expected to undergo another treatment plan requiring hospitalization during the study.
History of cardiovascular disease, inflammatory bowel disease, chronic fecal incontinence, prior pelvic radiotherapy, fixed anal stenosis/fibrosis, major psychiatric disorders (including cigarette, drug, or alcohol users), or hematologic .
Use of investigational drugs within 8 weeks or a period equal to five half-lives prior to screening, whichever is longer.
diseases Individuals who may be unavailable during the trial period, are unlikely to comply with the protocol, or are otherwise deemed unsuitable by the physician for any reason.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K60.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic anal fissure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:‪In this group, each patient receives 0.4 ml of Botox divided into two injections of equal volume on both the right and left lateral sides of the fissure. The injection is performed with a 27-gauge needle. The solution is injected close to the fissure on the lateral side. No sedation or local anesthesia will be used. Patients in the treatment group receive 20 units of botulinum toxin A (Botox 50 units per milliliter), then local anesthesia with all aseptic measures will be performed for PRP injection (ready-made PRP kits are used in this study). Anorectal dilatation is performed in the jack-knife position. Once the anal spasm is relieved, a speculum is placed in the anal canal and the fissure is observed on the clock indicator. The PRP sample is drawn and injected into the fissure bed to the submucosal layer with an insulin needle at a 45-degree angle. We wait for complete hemostasis to be achieved. Dressing is done with all aseptic precautions.‬</i_keyword>
      <i_keyword>Control group1: In this group, each patient receives 0.4 ml of Botox divided into two equal injections into the right and left lateral sides of the fissure. The injection is performed with a 27-gauge needle. The solution is injected close to the fissure on the lateral side. Sedation or local anesthesia will not be used. Patients in the treatment group receive 20 units of botulinum toxin A (50 units of Botox per ml).</i_keyword>
      <i_keyword>Control group2: In this group, patients apply a fingertip amount of diltiazem gel around their anus every 12 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: 0,1,6,12 weeks. Method of measurement: Improvement of post-defecation anal pain based on the Numerical Rating Scale (NRS): Changes in pain scores were measured at baseline (i.e., before the start of the study) and at 1, 6, and 12 weeks after the start of the study. Pain was assessed using the Numerical Rating Scale, ranging from 0 to 10, where 0 = no pain and 10 = worst possible pain.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Recurrence of the anal fissure. Timepoint: It is measured at 1 week, 6 weeks, and 12 weeks from the start date of the study. Method of measurement: Anatomical examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>univercity</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-11-22</approval_date>
        <contact_name>Ethics committee of lorestan  University of Medical Sciences</contact_name>
        <contact_address>kamalvand khoram abbad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
